1. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial;Heijerman;Lancet,2019
2. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele;Middleton;N Engl J Med,2019
3. Triple therapy for cystic fibrosis Phe508del-gating and -residual function genotypes;Barry;N Engl J Med,2021
4. Kaftrio. Summary of product characteristics. Available online: https://www.ema.europa.eu/en/documents/productinformation/kaftrio-epar-product-information.
5. Kalydeco. Summary of product characteristics. Available online: https://www.ema.europa.eu/en/documents/productinformation/kalydeco-epar-product-information.